Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03303794 · ClinicalTrials.gov registry record · Phase 3
0.25% Bupivacaine Versus a Mixture of 0.25% Bupivacaine and 1.3 % Liposomal Bupivacaine in Patients Undergoing Tka
A Phase 3 study, sponsored by Montefiore Medical Center.
- Terminated
- Registry status
- Phase 3
- Development phase
- 25
- Enrollment target
NCT03303794 is a Phase 3 study that was terminated before completion, run by Montefiore Medical Center. The registered enrollment target is 25 participants.
The verdict
NCT03303794, a Phase 3 study, was terminated before completion, sponsored by Montefiore Medical Center.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 25 participants
- Enrollment target
Study Summary
Total knee and hip replacements are some of the most common orthopedic procedures that require aggressive postoperative pain management. This management helps us to improve clinical outcomes such as participation in early physical therapy, hospital discharge, and patient satisfaction. Based on the recent anatomical evidence and the investigator's knowledge of the complexity of the knee joint innervation the investigator proposes a new regional anesthesia technique that provides a complete sensory blockade and better analgesia while preserving the quadriceps strength and avoiding the potential for foot drop caused by inadvertent blockade of the common peroneal nerve.
Interventions
- DRUG Exparel
- DRUG 0.25% bupivacaine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2017-10-25 |
| Est. Completion | 2018-06-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03303794
The ClinicalTrials.gov registry entry for NCT03303794 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Montefiore Medical Center, which has 345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Exparel is the first listed.
NCT03303794 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03303794 about?
NCT03303794 is a clinical study titled "0.25% Bupivacaine Versus a Mixture of 0.25% Bupivacaine and 1.3 % Liposomal Bupivacaine in Patients Undergoing Tka". Total knee and hip replacements are some of the most common orthopedic procedures that require aggressive postoperative pain management. This management helps us to improve clinical outcomes such as participation in early physical therapy, hospital discharge, and patient satisfaction. Based on the r...
What is the current status of trial NCT03303794?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 25 participants. The study started on 2017-10-25. Estimated completion is 2018-06-27.
What interventions are being tested in trial NCT03303794?
The interventions under investigation include: Exparel (DRUG), 0.25% bupivacaine (DRUG).
Who is sponsoring clinical trial NCT03303794?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.